



# Macrophage activation induces formation of the anti-inflammatory lipid cholesteryl-nitrolinoleate

Ana M. FERREIRA\*, Mariana I. FERRARI\*, Andrés TROSTCHANSKY†, Carlos BATTYANY†§, José M. SOUZA†, María N. ALVAREZ‡, Gloria V. LÓPEZ‡, Paul R. S. BAKER§, Francisco J. SCHOPFER§, Valerie O'DONNELL||, Bruce A. FREEMAN§<sup>1</sup> and Homero RUBBO†<sup>1</sup>

\*Department of Immunology, Faculty of Sciences, University of the Republic, Montevideo 11400, Uruguay, †Department of Biochemistry, Center for Free Radical and Biomedical Research, Faculty of Medicine, University of the Republic, Montevideo 11800, Uruguay, ‡Department of Organic Chemistry, Faculty of Sciences, University of the Republic, Montevideo 11800, Uruguay, §Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, U.S.A., and ||Department of Medical Biochemistry, University of Wales College of Medicine, Cardiff CF14 4XN, U.K.

Nitroalkene derivatives of fatty acids act as adaptive, anti-inflammatory signalling mediators, based on their high-affinity PPAR $\gamma$  (peroxisome-proliferator-activated receptor  $\gamma$ ) ligand activity and electrophilic reactivity with proteins, including transcription factors. Although free or esterified lipid nitroalkene derivatives have been detected in human plasma and urine, their generation by inflammatory stimuli has not been reported. In the present study, we show increased nitration of cholesteryl-linoleate by activated murine J774.1 macrophages, yielding the mononitrated nitroalkene CLNO<sub>2</sub> (cholesteryl-nitrolinoleate). CLNO<sub>2</sub> levels were found to increase ~20-fold 24 h after macrophage activation with *Escherichia coli* lipopolysaccharide plus interferon- $\gamma$ ; this response was concurrent with an increase in the expression of NOS2 (inducible nitric oxide synthase) and was inhibited by the •NO (nitric oxide) inhibitor L-NAME (N<sup>G</sup>-nitro-

L-arginine methyl ester). Macrophage (J774.1 and bone-marrow-derived cells) inflammatory responses were suppressed when activated in the presence of CLNO<sub>2</sub> or LNO<sub>2</sub> (nitrolinoleate). This included: (i) inhibition of NOS2 expression and cytokine secretion through PPAR $\gamma$  and •NO-independent mechanisms; (ii) induction of haem oxygenase-1 expression; and (iii) inhibition of NF- $\kappa$ B (nuclear factor  $\kappa$ B) activation. Overall, these results suggest that lipid nitration occurs as part of the response of macrophages to inflammatory stimuli involving NOS2 induction and that these by-products of nitro-oxidative reactions may act as novel adaptive down-regulators of inflammatory responses.

**Key words:** cholesteryl-nitrolinoleate, haem oxygenase-1, inducible nitric oxide synthase, inflammation, lipid nitration, macrophage.

## INTRODUCTION

Nitro-derivatives of unsaturated fatty acids have been structurally characterized and quantified in plasma, red blood cells and urine of both healthy and hypercholesterolaemic humans [1–3]. Although dietary sources may contribute to tissue nitro-fatty acid levels, these species can also be formed by oxidative and nitrative reactions associated with inflammation. Mechanisms known to mediate fatty acid nitration to nitroalkene derivatives include nucleophilic (nitronium group, NO<sub>2</sub><sup>+</sup>) and/or radical (nitrogen dioxide, •NO<sub>2</sub>) addition reactions with olefinic carbons [2,4,5]. Nitroalkene fatty acid derivatives display pluripotent cell signalling actions that limit inflammatory responses. In particular, LNO<sub>2</sub> (nitrolinoleate; 9, 10, 12 and 13-nitro-9,12-*cis*-octadecadienoic acid) and OANO<sub>2</sub> (nitro-oleate; 9 and 10-nitro-9-*cis*-octadecenoic acid) activate PPAR $\gamma$  (peroxisome-proliferator-activated receptor  $\gamma$ ), representing more potent or higher-affinity ligands for PPAR $\gamma$  than various putative endogenous ligands (i.e. lysophosphatidic acid, conjugated linoleate and 15-deoxy- $\Delta^{12,14}$ -prostaglandin J<sub>2</sub>) and rivalling the potency of synthetic thiazolidinedione agonists [3,6]. Nitroalkene signalling via PPAR $\gamma$  activation modulates expression of metabolic- and inflammatory-related genes [7–13]. In particular, LNO<sub>2</sub> induces pre-adipocyte differentiation and aP2 (adipocyte P2) expression,

and increases glucose uptake by adipocytes [6]. Fatty acid nitroalkene derivatives also display PPAR $\gamma$ -independent actions on various cell types; for example, they decay in aqueous milieu to •NO (nitric oxide) [14,15], thus promoting vessel relaxation via endothelial-independent, cGMP-dependent pathways [16]. This latter property is readily inhibited by intercalation of nitroalkenes into organized lipid micelles or membranes [14]. Other anti-inflammatory actions of LNO<sub>2</sub> include modulation of cytokine secretion by macrophages via a mechanism involving interference with NF- $\kappa$ B (nuclear factor  $\kappa$ B) activation [17], as well as cAMP-mediated inhibition of platelet and neutrophil function [18,19]. In human aortic endothelial cells, LNO<sub>2</sub> also potently induces tissue-protective HO-1 (haem oxygenase-1) expression by •NO-independent mechanisms [20].

The nitration of the principal oxidizable lipid in human blood, CL (cholesteryl-linoleate) has been detected [21]. CLNO<sub>2</sub> (cholesteryl-nitrolinoleate) is present in healthy humans at plasma concentrations of 77 ± 11 nM [22], representing one component of net esterified LNO<sub>2</sub> [2]. CLNO<sub>2</sub> behaves similarly to LNO<sub>2</sub>, with respect to an ability to release •NO in aqueous milieu and promote endothelium-independent vasorelaxation [15]. To date, oxidative and nitro-oxidative inflammatory reactions have not been reported to generate free or esterified nitrated fatty acids in the biological milieu. Moreover, the biological properties of the

Abbreviations used: BCA, bichononic acid; BMDM, bone-marrow-derived macrophage; CL, cholesteryl-linoleate; CLNO<sub>2</sub>, cholesteryl-nitrolinoleate; DAF-2DA, 4,5-diaminofluorescein diacetate; DAPI, 4',6-diamidino-2-phenylindole; DMEM, Dulbecco's modified Eagle's medium; EPI, enhanced product ion; ESI-MS, electrospray ionization MS; ESI-MS/MS, ESI-tandem MS; FCS, fetal calf serum; HO-1, haem oxygenase 1; IFN $\gamma$ , interferon  $\gamma$ ; IL, interleukin; LA, linoleate; L-NAME, N<sup>G</sup>-nitro-L-arginine methyl ester; LNO<sub>2</sub>, nitrolinoleate; LPS, lipopolysaccharide; MRM, multiple reaction monitoring; NF- $\kappa$ B, nuclear factor  $\kappa$ B; NOS2, inducible nitric oxide synthase; OANO<sub>2</sub>, nitro-oleate; PPAR $\gamma$ , peroxisome-proliferator-activated receptor  $\gamma$ ; Rf, retention factor; TNF, tumour necrosis factor.

<sup>1</sup> Correspondence may be addressed to either of these authors (email hrubbo@fmed.edu.uy or freerad@pitt.edu).

predominant reservoir of oxidized and nitrated membrane and lipoprotein derivatives, esterified lipids, have not been studied. In the present study, we reveal significant increases in the formation of CLNO<sub>2</sub> during macrophage activation and an ability of this nitrated esterified lipid to down-regulate monocyte/macrophage activation.

## EXPERIMENTAL

### Reagents

Inorganic salts, culture medium [RPMI 1640 and DMEM (Dulbecco's modified Eagle's medium)], chloroquine, cycloheximide, DAPI (4',6-diamidino-2-phenylindole), mouse recombinant IFN $\gamma$  (interferon  $\gamma$ ), LPS (lipopolysaccharide; *Escherichia coli* serotype O127:B8), L-NAME (*N*<sup>G</sup>-nitro-L-arginine methyl ester) and PMA were purchased from Sigma Chemicals. LA (linoleate) and CL were from Nu-Check Prep. Silica gel HF TLC plates were from Uniplate, Analtech. Solvents (HPLC grade or better) were purchased from Fisher Scientific or Pharmco. Alexa Fluor<sup>®</sup> 488 was from Invitrogen, Molecular Probes. DAF-2DA (4,5-diaminofluorescein diacetate) was from Alexis. FCS (fetal calf serum) was from Bio Whittaker. NOC-18 (an  $\bullet$ NO donor) was from Dojindo Laboratories. Rosiglitazone was from Cayman Chemicals. SuperSignal chemiluminescent substrate was from Pierce. Affinity-purified rabbit anti-NOS2 (NOS2 is inducible NO synthase) IgG was from Sigma. Monoclonal antibodies (anti-human CD36 and anti-human CD45), as well as FITC-conjugated immunoglobulins used for flow cytometry were from BD Biosciences. A BCA (bicinchoninic acid) protein assay kit, polyclonal rabbit anti-(NF- $\kappa$ B p65) and peroxidase-conjugated anti-rabbit IgG were from Calbiochem. Rabbit anti-mouse HO-1 was from Stressgen Biotechnologies.

### Cell culture

J774.1 murine macrophage-like cells (American Type Culture Collection) were maintained by passage in DMEM containing 4 mM L-glutamine, and supplemented with 10% heat-inactivated FCS. THP-1 human monocyte-like cells (American Type Culture Collection) were cultured in RPMI 1640 medium containing 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 1% sodium pyruvate, 10 mM Hepes and supplemented with 10% heat-inactivated FCS. BMDM (bone-marrow-derived macrophages) were obtained as described previously [23]. Briefly, cells were harvested from femur and tibias of 6–10-week-old Balb/c mice [DILAVE (Veterinary Laboratories Division of the General Direction of Livestock Services, Uruguay)], cultured in DMEM supplemented with 10% heat-inactivated FCS and 15% L929 conditioned medium as a source of M-CSF (macrophages colony-stimulating factor). On day 7, cells were detached, purified by centrifugation (150g for 10 min at 20°C) and plated at  $5 \times 10^5$  cells/well. Animal experimentation was carried out in accordance with the legal requirements of the Honorary Commission on Animal Experimentation (CHEA), University of the Republic, Uruguay.

### Synthesis and characterization of CLNO<sub>2</sub> and LNO<sub>2</sub>

CLNO<sub>2</sub> was synthesized by the reaction of CL with nitrite at acid pH as described in [22]. Briefly, CL (1.5 mmol) was added to a degassed mixture of hexane and 1% sulfuric acid (1:1, v/v, 4 ml final vol.) followed by the addition of sodium nitrite in two portions at 15 min intervals (7.5 mmol total). The biphasic reaction system was vigorously stirred using a stoppered round-bottom flask and a stir bar (30 min at 25°C). Following this reaction, the organic layer was separated and dried under a stream of nitrogen. The

reaction mixture was diluted with methylene chloride and lipids were separated by preparative TLC on silica gel using a mixture of hexane/ether (80:20, v/v) as the solvent. The separated lipid components were detected by UV absorption and by charring following the reaction with concentrated sulfuric acid. Regions of silica containing nitrated lipids were extracted, dried under vacuum, dissolved in propan-2-ol and stored at  $-20^\circ\text{C}$  [24]. The obtained products were characterized by MS on a 2000 Q-Trap (Applied Biosystems/MDS Sciex) using ESI-MS (electrospray ionization MS) and ESI-MS/MS (ESI-tandem MS; positive mode, direct injection in propan-2-ol containing 4 mM ammonium acetate, and detection of  $[\text{M} + \text{NH}_4]^+$  ammonium adducts). NMR analysis of CLNO<sub>2</sub> involved <sup>1</sup>H, <sup>13</sup>C and bi-dimensional studies recorded in CDCl<sub>3</sub> (Bruker 400 MHz). Quantitation of CLNO<sub>2</sub> was done by gravimetry as well as by determining the nitrogen content using chemiluminescent nitrogen analysis (Antek Instruments) as described in [3]. LNO<sub>2</sub> and [<sup>13</sup>C]LNO<sub>2</sub> were synthesized, purified and quantified as described previously [2,3].

### Quantification of CLNO<sub>2</sub> in macrophages

Confluent monolayers of J774.1 cells were stimulated with LPS/IFN $\gamma$  or PBS, pH 7.2 (control). The NOS inhibitor L-NAME (5 mM) was included in some assays to assess whether the CLNO<sub>2</sub> generation was influenced by  $\bullet$ NO generation during macrophage activation. After 6 or 24 h incubation, nitrite was measured in cell supernatants using Griess reagent [25] and cells were recovered for lipid extraction [24]. A [<sup>13</sup>C]CLNO<sub>2</sub> internal standard could not be prepared, owing to loss of the nitro group during [<sup>13</sup>C]LNO<sub>2</sub>-cholesterol esterification reactions. Alternatively, during the monophasic stage of lipid extraction, a known amount of [<sup>13</sup>C]LNO<sub>2</sub> was added as an internal standard to correct for sample-to-sample differences in extraction and handling efficiency. CLNO<sub>2</sub> was determined by HPLC ESI-MS/MS. Both CLNO<sub>2</sub> and [<sup>13</sup>C]LNO<sub>2</sub> were eluted from a 150 mm  $\times$  2.1 mm C<sub>18</sub> GraceVydac column (5  $\mu$ m particle size) using an isocratic solvent consisting of 60 mM propan-2-ol/40 mM acetonitrile/4 mM ammonium acetate. For quantitative analysis, two MRM (multiple reaction monitoring) transitions were monitored:  $m/z$  711  $\rightarrow$  369 for the ammonium adduct of CLNO<sub>2</sub> and  $m/z$  342  $\rightarrow$  297 for [<sup>13</sup>C]LNO<sub>2</sub> in the positive and negative ion mode respectively [3,22]. The relative amount of CLNO<sub>2</sub> present in samples was determined by comparing the peak areas of CLNO<sub>2</sub> and [<sup>13</sup>C]LNO<sub>2</sub> standards in control and treated samples. The identity of CLNO<sub>2</sub> was confirmed by both monitoring fragmentation of CLNO<sub>2</sub> to LNO<sub>2</sub> ( $m/z$  711  $\rightarrow$  326) and generating EPI (enhanced product ion) spectra of the  $m/z$  711 product. Owing to the lack of the [<sup>13</sup>C]CLNO<sub>2</sub> standard, absolute quantification was not obtained by this method; rather, a relative increase with respect to paired controls is reported (the ratio of the peak areas of CLNO<sub>2</sub> relative to the internal standard). In addition, to better estimate the CLNO<sub>2</sub> content in macrophages, we constructed an external CLNO<sub>2</sub> calibration curve using known concentrations of synthetic CLNO<sub>2</sub>. This procedure, although revealing, on occasion may not yield entirely accurate values of CLNO<sub>2</sub> concentrations in biological samples, because of the potential loss of CLNO<sub>2</sub> during sample lipid extraction.

### Analysis of CLNO<sub>2</sub> effects on NOS2 induction

Macrophages (confluent monolayers of J774.1 or BMDM as indicated) were exposed to LPS (0.5–1  $\mu$ g/ml) in the presence or absence of IFN $\gamma$  (400 units/ml). Reactions were performed in DMEM containing 10% (v/v) FCS with addition of vehicle or indicated concentrations of CL, CLNO<sub>2</sub> or LNO<sub>2</sub>. Nitroalkenes were added prior to (6 and 20 h), or concurrently

with, the stimulus. After 4–5 h activation, supernatants were discarded, cells were washed and NOS2 expression was assessed immunocytochemically using anti-NOS2 antibodies or by monitoring  $\bullet$ NO generation using the cell-permeant fluorescence indicator DAF-2DA [26]. Assays using rosiglitazone (10–50  $\mu$ M) and NOC-18 (0.1–50  $\mu$ M) were also performed to evaluate potential mitigation by PPAR $\gamma$  ligand and  $\bullet$ NO actions respectively. Examination of the nitroalkene effect on NOS2 activity was performed using cycloheximide, an inhibitor of protein translation; cells were pre-activated with LPS for 6 h to induce NOS2, and then cycloheximide (5  $\mu$ M) was added together with nitroalkenes (CLNO<sub>2</sub> or LNO<sub>2</sub>) or vehicle (control), and NOS2 expression was measured 3 h later. Cell viability after treatment with the different agents under study was examined using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide].

### CLNO<sub>2</sub> modulation of IL (interleukin)-1 $\beta$ and TNF (tumour necrosis factor) secretion

In order to quantify in parallel cytokine and CD36 expression (see below) we used human THP-1 macrophages, since previous studies showed that cytokine secretion by murine and human macrophages were similarly affected by nitroalkenes [17]. Briefly, cells were seeded at  $5 \times 10^5$  cells/well and stimulated with 50 ng/ml PMA in the presence of 10–50  $\mu$ M CL, CLNO<sub>2</sub> or vehicle. Cells were also activated in the presence of LA, LNO<sub>2</sub> or rosiglitazone. After 20 h of culture, cell supernatants were collected and analysed for IL-1 $\beta$  and TNF levels by capture ELISA (OptEIA sets; BD Biosciences) using antibody pairs and protocols as recommended by the manufacturer.

### Analysis of CD36 induction by CLNO<sub>2</sub>

THP-1 cells ( $5 \times 10^5$  cells/well) were stimulated with 50 ng/ml PMA in the presence of nitroalkenes (CLNO<sub>2</sub> or LNO<sub>2</sub>), their lipid precursors (CL, LA), rosiglitazone or vehicle (control). After 20–22 h stimulation, the expression of CD36 and CD45 was analysed by flow cytometry (FACSCalibur system; BD Biosciences) using mouse monoclonal antibodies. The increase in CD36 or CD45 expression (relative increase) was calculated as the ratio between the fluorescence intensity (median values) obtained for treated and control cells.

### HO-1 induction by CLNO<sub>2</sub>

Induction of HO-1 was analysed in cells incubated with CLNO<sub>2</sub> or LNO<sub>2</sub>. Treated cells were rinsed once with ice-cold PBS, quickly frozen and then lysed in 10 mM Hepes (pH 7.9) containing 10 mM KCl, 1.5 mM MgCl<sub>2</sub>, 1 mM DTT (dithiothreitol) and a mixture of protease inhibitors. Insoluble material was removed by centrifugation (5000 g at 4°C for 5 min). Supernatants were collected and the protein concentration was determined using a BCA protein assay. Lysates (25–30  $\mu$ g of protein) were electrophoresed on SDS/PAGE (10% gels) and electrotransferred on to nitrocellulose membranes. Western blot analysis was performed using rabbit anti-(HO-1) antibodies followed by a peroxidase-conjugated secondary antibody. SuperSignal chemiluminescent substrate was used for development.

### Analysis of CLNO<sub>2</sub> effects on NF- $\kappa$ B activation

J774.1 cells were stimulated with LPS (1 h, 37°C, 5% CO<sub>2</sub>) in the presence or absence of nitroalkenes. Afterwards, nuclear and cytoplasmic extracts were prepared as described previously [27]. Proteins (25  $\mu$ g) were separated by SDS/PAGE (10% gels) and transferred on to nitrocellulose membranes. Western blot analysis was performed using an anti-(NF- $\kappa$ B p65) antibody, followed by a

goat anti-rabbit IgG conjugated to peroxidase. Development was performed using the SuperSignal chemiluminescent substrate.

### Statistical analysis


Results are shown as means  $\pm$  S.D. Differences between mean values were evaluated using a Tukey–Kramer multiple comparison test and were considered significant at  $P < 0.05$ .

## RESULTS AND DISCUSSION

### Macrophage activation by inflammatory stimuli generates CLNO<sub>2</sub>


To address whether nitrate inflammatory reactions occurring during macrophage activation led to nitration of sterol esters, we compared the CLNO<sub>2</sub> content between LPS/IFN $\gamma$ -activated and control macrophages. For that purpose we first synthesized a CLNO<sub>2</sub> standard using methods previously described [22], by the reaction of CL with nitrite at acidic pH. From preparative TLC, two bands were separated [arrows, Figure 1A, termed CLNO<sub>2</sub> top and bottom isomers in reference to chromatographic Rf (retention factor) properties], and then analysed by positive ion ESI-MS (Figure 1B). The two bands displayed an  $m/z$  of 711, characteristic of the ammonium adduct of CLNO<sub>2</sub> ( $[M + NH_4]^+$ ). ESI-MS/MS of the  $m/z$  711 species yielded daughter ions of  $m/z$  369 (cholesterol-OH)<sup>+</sup>, 326 (LNO<sub>2</sub>)<sup>+</sup> and 279 [loss of the nitro group, (LNO<sub>2</sub>-HNO<sub>2</sub>)<sup>+</sup>] (Figure 1B, inset). NMR analysis of these two bands (see Supplementary Figure S1 at <http://www.BiochemJ.org/bj/417/bj4170223add.htm>) confirmed that nitration occurred on the acyl moiety of CL and corresponded to nitroalkene isomers (Figure 1C, termed CLNO<sub>2</sub> top and bottom isomers, in reference to chromatographic Rf properties). The synthetic CLNO<sub>2</sub> standard was then characterized by reverse-phase HPLC/MS, using MRM detection for two specific transitions:  $m/z$  711  $\rightarrow$  369 and  $m/z$  711  $\rightarrow$  326, which correspond to CLNO<sub>2</sub> fragmentation to cholesterol and LNO<sub>2</sub> respectively (Figure 2A). Both top and bottom CLNO<sub>2</sub> isomers eluted at the same retention time (9.5 min) and the  $m/z$  711  $\rightarrow$  326 transition ion intensity was lower. The identity of these species was confirmed by EPI of the  $m/z$  711 product (Figure 2A, right-hand panel).

CLNO<sub>2</sub> was eluted from lipid fractions of either activated or control macrophages, showing the same HPLC profile as the CLNO<sub>2</sub> standard (Figures 2B and 2C respectively). The identity of these species was also confirmed by EPI of the  $m/z$  711 product (Figure 2B). In the case of control macrophages, HPLC/MS analysis yielded weak ion intensities at these MRM transitions (detection using  $m/z$  711  $\rightarrow$  326 transition produced almost no signal; results not shown). For CLNO<sub>2</sub> quantification, the content of CLNO<sub>2</sub> was determined by comparing the peak areas of CLNO<sub>2</sub> (scanned using  $m/z$  711  $\rightarrow$  369 transition) and [<sup>13</sup>C]LNO<sub>2</sub> (internal standard, scanned using  $m/z$  342  $\rightarrow$  297). Results are presented as area ratios of analyte to [<sup>13</sup>C]LNO<sub>2</sub> (Figure 2D). Unstimulated murine J774.1 macrophages contained levels of CLNO<sub>2</sub> lower than that detected in LPS plus IFN $\gamma$ -activated macrophages; the latter displayed a 3-fold and 19-fold increase in CLNO<sub>2</sub> levels following 6 and 24 h activation respectively (Figure 2D). Using an external CLNO<sub>2</sub> calibration curve, we estimated a CLNO<sub>2</sub> content of 100–300 pmol/10<sup>6</sup> cells following 24 h of inflammatory activation. As expected, CLNO<sub>2</sub> formation by activated macrophages was inhibited by L-NAME (Figure 2D), which also inhibited 50–60% of nitrite formation in the culture medium (results not shown), supporting the contribution of  $\bullet$ NO-derived species towards CL nitration. Furthermore, the increase of CLNO<sub>2</sub> in activated macrophages occurred in concert with increased NOS2 activity (Figure 2E). At longer activation times



**Figure 1** Characterization of CLNO<sub>2</sub>

(A) TLC analysis of products obtained from nitrite treatment of CL, showing two main nitrated products (arrows) and non-reacted CL (arrowhead). These products were extracted from the silica, dried under vacuum and analysed by ion-trap MS (positive mode, direct injection, propan-2-ol containing 4 mM ammonium acetate). (B) MS spectra of the ammonium adducts of CLNO<sub>2</sub>; insert: MS/MS of parent molecule showing LNO<sub>2</sub> as a daughter ion. (C) <sup>1</sup>H-, <sup>13</sup>C-NMR spectrometry and two-dimensional COSY, HMBC (heteronuclear multiple bond correlation) and HMQC (heteronuclear single quantum correlation) analysis. CLNO<sub>2</sub> bottom data correspond to cholesteryl-10-nitrooleate (I) and its conjugated isomer (II). CLNO<sub>2</sub> top data correspond to a mixture of cholesteryl-9-nitrooleate and (I).



**Figure 2** CL nitration generated CLNO<sub>2</sub> in activated macrophages


J774.1 cells were stimulated with LPS (1  $\mu$ g/ml) plus IFN $\gamma$  (400 units/ml). After 6 or 24 h incubation, cells were recovered, lipids extracted and the presence of CLNO<sub>2</sub> was analysed by HPLC/MS using the MRM scan mode (*m/z* 711  $\rightarrow$  369 and *m/z* 711  $\rightarrow$  326). HPLC elution profiles of the CLNO<sub>2</sub> standard (**A**) and lipid extractions from activated (**B**) and non-activated (**C**) macrophages are shown. Representative EPI of the *m/z* 711 product present in eluted CLNO<sub>2</sub> from the standard (**A**, right-hand panel) and activated macrophage (**B**, right-hand panel) lipid fractions. (**D**) Quantification of CLNO<sub>2</sub> relative to the internal standard [<sup>13</sup>C]LNO<sub>2</sub> in control and activated cells as well as in the presence of L-NAME (5 mM). Results are expressed as the means  $\pm$  S.E.M. ( $n=4$ ). \* $P < 0.05$  compared with controls,  $^{\&}P < 0.05$  compared with 6 h activation and  $^{\#}P < 0.05$  compared with L-NAME. (**E**) Time course of NOS2 expression in cells stimulated with LPS/IFN $\gamma$ ; NOS2 activity was followed by fluorimetry using DAF-2DA. Results are expressed as means  $\pm$  S.D. ( $n=4$ ).

(24 h) when induced levels of NOS2 activity had significantly decreased, the cumulative content of CLNO<sub>2</sub> was 19-fold greater than controls (Figure 2E). A concomitant increase in nitrite levels in the medium was observed over time, with levels 10-fold greater after 24 h compared with 6 h stimulation. In summary, macrophage activation by LPS and IFN $\gamma$  led to acyl chain nitration of CL, revealing that nitration of esterified unsaturated fatty acids takes place in a biological milieu and, particularly, in an inflammatory condition where NOS2 is induced.

#### CLNO<sub>2</sub> and LNO<sub>2</sub> inhibit the generation of inflammatory mediators by monocytes/macrophages

As already mentioned, fatty-acid-derived nitroalkenes are capable of modulating the expression of inflammatory genes. Thus the

formation of CLNO<sub>2</sub> during macrophage activation may influence cell functions through LNO<sub>2</sub> release by cell cholesteryl ester hydrolases. Moreover, in the case of macrophages, activation by inflammatory stimulus could increase neutral cholesteryl esterase activity [28], potentially favouring LNO<sub>2</sub> release. Thus we studied the effect of CLNO<sub>2</sub> and LNO<sub>2</sub> on the generation of inflammatory mediators by monocytes/macrophages. First, the effect of these nitroalkenes on  $\bullet$ NO production was investigated in murine macrophages (BMDM and J774.1 cells); cells were treated for various time intervals relative to the addition of LPS (alone or plus IFN $\gamma$ ) with CLNO<sub>2</sub> (bottom and top isomers), LNO<sub>2</sub> and their corresponding precursors (CL and LA). Nitroalkene effects on  $\bullet$ NO generation by BMDM and J774.1-activated macrophages were comparable: CLNO<sub>2</sub> (both isomers) and LNO<sub>2</sub> caused a dose-dependent reduction of  $\bullet$ NO generation, whereas CL




**Figure 3** CLNO<sub>2</sub> inhibited \*NO generation by activated macrophages

Activation of mouse macrophages (J774.1 cells and BMDM) was performed in the presence or absence of the indicated molecules, and after 5 h incubation \*NO was measured by fluorimetry. **(A)** Nitroalkenes were added concurrently ( $t = 0$ hs) or 20 h ( $t = 20$ hs) prior to LPS stimulation. NOS2 activity is expressed relative to the control (vehicle) and values correspond to means  $\pm$  S.D. ( $n = 3$ ). **(B)** Cells were activated with LPS and nitroalkenes (20  $\mu$ M LNO<sub>2</sub> or 50  $\mu$ M CLNO<sub>2</sub>) added together with the activating molecules (black bars) or at 6 h post-activation in the presence of cycloheximide (grey bars). NOS2 activity was measured at 9 h post-stimulation by fluorimetry. Results are expressed as the means  $\pm$  S.D. ( $n = 3$ ). In all cases \* indicates a statistical significance ( $P < 0.05$ ) compared with the control [vehicle (veh)].

and LA had no effect (Figures 3A and Supplementary Figure S2 at <http://www.BiochemJ.org/bj/417/bj4170223add.htm>). The inhibitory effect of CLNO<sub>2</sub> on \*NO generation was more pronounced when added to macrophages 6 h (results not shown) and 20 h prior to activation with LPS alone (Figure 3A). In contrast, LNO<sub>2</sub> inhibition was independent of the time interval at which it was added in relation to LPS, where LNO<sub>2</sub> was the strongest inhibitor of \*NO generation (1.25  $\mu$ M LNO<sub>2</sub> caused a reduction comparable with 5  $\mu$ M CLNO<sub>2</sub>). To address whether these inhibitory effects on \*NO generation were linked to modulation of NOS2 expression, we performed experiments in which cells were pre-activated for 6 h to induce NOS2 expression and then nitroalkenes were added together with the protein translation inhibitor cycloheximide. An inhibitory effect

of CLNO<sub>2</sub> and LNO<sub>2</sub> on \*NO generation was not observed in these conditions (Figure 3B), suggesting that nitroalkene actions were dependent on inhibiting NOS2 gene expression, rather than inhibiting NOS2 catalytic activity. Immunohistochemical analysis of NOS2 expression by activated macrophages confirmed that CLNO<sub>2</sub> down-regulated NOS2 expression and that LNO<sub>2</sub> had more potent inhibitory effects (Figure 4). Under these conditions, CLNO<sub>2</sub> or LNO<sub>2</sub> did not induce changes in cell viability (Supplementary Figure S3 at <http://www.BiochemJ.org/bj/417/bj4170223add.htm>) or protein levels.

It has recently been shown that nitroalkenes, particularly LNO<sub>2</sub> and OANO<sub>2</sub>, are capable of modulating the production of inflammatory cytokines (IL-6 and TNF $\alpha$ ) by human, as well as murine, macrophages [17]. Thus we also explored whether CLNO<sub>2</sub> was



**Figure 4** CLNO<sub>2</sub> modulation of NOS2 expression

Mouse J774.1 cells at confluence were stimulated for 6 h with LPS plus IFN $\gamma$  in the presence or absence of 50  $\mu$ M CLNO<sub>2</sub> (top and bottom isomers) and analysed by immunofluorescence for NOS2 expression (left-hand panels). Cell nuclei were stained using DAPI as a control (right-hand panels).

able to modulate cytokine secretion by monocytes/macrophages, determining the extent of IL-1 $\beta$  and TNF secretion by human THP-1 cells stimulated with PMA. CLNO<sub>2</sub> and LNO<sub>2</sub> induced a significant decrease in pro-inflammatory cytokine secretion ( $P < 0.05$ ; Figure 5) under conditions where nitroalkenes were added concurrently with the stimulus. This inhibition required greater nitroalkene concentrations than those previously reported [17]. Among other reasons, discrepancies may be due to the presence in our assays of a 10-fold higher concentration of FCS during cell stimulation; this may have caused a reduction in the level of available nitroalkene for interacting with cells.


LNO<sub>2</sub> was a stronger modulator of NOS2 and cytokine expression than CLNO<sub>2</sub>. Since nitroalkenes have the capability to signal by directly interacting with cellular targets (e.g. receptors or nucleophilic reaction centres), the differences in potency observed may be explained by a more limited access of CLNO<sub>2</sub> to those targets, as the cholesterol moiety can be expected to decrease solubility and diffusional properties in cellular compartments. Alternatively, as mentioned above, CLNO<sub>2</sub> may express activity only upon hydrolytic release of fatty acid nitro-derivatives by cell lipases and esterases; if this were the case, this sterol ester derivative may be relevant as a cellular reservoir of LNO<sub>2</sub> in hydrophobic compartments. In our macrophage studies, it is plausible that CLNO<sub>2</sub> may traffic to lysosomes, and LNO<sub>2</sub> released by acid cholesteryl ester hydrolase may contribute to the observed effects. To address the possible contribution of hydrolytically released LNO<sub>2</sub> to the signalling actions of CLNO<sub>2</sub>

we performed studies in the presence of chloroquine, an inhibitor of lysosome acidification, which is necessary for the activity of acid cholesteryl ester hydrolases. When CLNO<sub>2</sub> was added concurrently with LPS, CLNO<sub>2</sub>-mediated NOS2 down-regulation was not affected by chloroquine, suggesting that the release of LNO<sub>2</sub> from CLNO<sub>2</sub> was not required (Supplementary Figure S3). Long-term chloroquine treatment of macrophages resulted in increased cell susceptibility to LPS activation, as shown by higher percentages of cell death after 4–5 h of LPS stimulation. Thus definitive assessment of the contribution of LNO<sub>2</sub> release to the inhibitory effects of CLNO<sub>2</sub> requires further study (e.g. silencing of cholesteryl ester hydrolases).

Overall, these results showed that CLNO<sub>2</sub> and LNO<sub>2</sub> suppressed NOS2 and cytokine expression by macrophages in response to inflammatory stimuli, suggesting that CLNO<sub>2</sub> formation upon macrophage activation, directly or indirectly via LNO<sub>2</sub>, may serve an adaptive role by contributing to the attenuation of inflammatory gene expression.

#### PPAR $\gamma$ and •NO are not involved in CLNO<sub>2</sub>- and LNO<sub>2</sub>-dependent inhibition of the production of inflammatory mediators by monocytes/macrophages

Nitroalkenes are potent PPAR $\gamma$  ligands [3,6] with PPAR $\gamma$  a critical mediator of the regulation of macrophage inflammatory responses. For exploring whether the inhibitory effects of CLNO<sub>2</sub> and LNO<sub>2</sub> on NOS2 induction in LPS-activated macrophages



**Figure 5** Effects of CLNO<sub>2</sub>, LNO<sub>2</sub> and rosiglitazone on cytokine secretion

THP-1 cells were differentiated with 50 ng/ml PMA in the presence of the molecules indicated. After 20 h incubation, supernatants were assessed for IL-1 $\beta$  (A) and TNF (B) by ELISA. Results are expressed as means  $\pm$  S.D. ( $n = 3$ ). \* indicates a statistical significance ( $P < 0.05$ ) compared with control.


occurred via PPAR $\gamma$ , we first evaluated, using THP-1 cells, the ability of nitroalkenes to induce the expression of CD36, a PPAR $\gamma$ -regulated gene product in monocytes/macrophages. CLNO<sub>2</sub> showed no influences on CD36 expression, even at 20–50  $\mu$ M (Figure 6A). In contrast, LNO<sub>2</sub> and the high-affinity PPAR $\gamma$  ligand rosiglitazone (10–50  $\mu$ M) induced a significant increase in CD36 expression ( $P < 0.05$ ; Figures 6B and 6C). In these assays, CD45 expression was analysed in parallel as a control, and showed no alteration by either nitroalkene or rosiglitazone treatment. These results confirmed that CLNO<sub>2</sub> does not display significant PPAR $\gamma$  ligand activity, and is consistent with the fact that nitroalkenes, which are high-affinity PPAR $\gamma$  ligands [3], lose receptor-activating capability upon ester derivatization of the carboxylic acid. Furthermore, the well-known PPAR $\gamma$  activator rosiglitazone was tested to address the contribution of PPAR $\gamma$  to the observed anti-inflammatory actions of CLNO<sub>2</sub> and LNO<sub>2</sub>. Rosiglitazone did not inhibit cytokine production (Figure 5) or  $\cdot$ NO generation (results not

shown) by activated monocytes/macrophages, confirming that the modulatory actions of nitroalkenes on these cells were not PPAR $\gamma$ -dependent. These results are consistent with previous observations [17], and with the fact that the anti-inflammatory effects of electrophilic PPAR $\gamma$  agonists such as 15-deoxy- $\Delta^{12,14}$ -prostaglandin J<sub>2</sub> predominantly occur via PPAR $\gamma$ -independent mechanisms [29,30].

The potential contribution of nitroalkene-derived  $\cdot$ NO to inhibition of NOS2 expression was also examined. LPS- and LPS/IFN $\gamma$ -induced generation of  $\cdot$ NO by macrophages was not affected by the  $\cdot$ NO donor NOC-18 (1–50  $\mu$ M), even at concentrations that far exceed any possible  $\cdot$ NO concentration that might be derived from nitroalkene decay in assay systems (results not shown). Therefore CLNO<sub>2</sub>-mediated inhibition of macrophage activation could not be explained by an ability to release  $\cdot$ NO, as described previously [17,31,32]. Of note,  $\cdot$ NO-mediated attenuation of NOS2 expression frequently requires high, non-biological concentrations of  $\cdot$ NO [32] that may be transduced by mechanisms shown in the present study. Thus additional pathways appear to be involved in signalling actions linked to nitroalkene-mediated control of NOS2 expression.

#### CLNO<sub>2</sub> and LNO<sub>2</sub> mediate induction of HO-1 expression in macrophages

The induction of HO-1 is an endogenous cytoprotective pathway triggered by a variety of stress-related signals and electrophilic species [33,34]. HO-1 catalyses the oxidative degradation of haem to biliverdin, releasing carbon monoxide (CO) and the chelated Fe<sup>2+</sup>. These products exert anti-oxidant and anti-inflammatory actions; thus attention has been recently devoted to CO, which possesses intriguing signalling properties affecting numerous critical cellular functions including proliferation and apoptosis, as well as the generation of inflammatory mediators [35]. Fatty acid nitroalkene derivatives (LNO<sub>2</sub>, OANO<sub>2</sub>) induce HO-1 expression in endothelial cells [20] and RAW264.7 macrophages [17]. Thus we explored whether CLNO<sub>2</sub>, as well as LNO<sub>2</sub>, were capable of driving HO-1 expression in macrophages. As shown in Figure 7(A), HO-1 was induced in J774.1 macrophages by CLNO<sub>2</sub> and LNO<sub>2</sub>, but not by their respective native fatty acid precursors, with CLNO<sub>2</sub> less potent than LNO<sub>2</sub> in up-regulating HO-1 expression. Of relevance, the time course of NOS2 and HO-1 expression diverged in macrophages activated with LPS in the presence or absence of CLNO<sub>2</sub>. HO-1 was induced after approx. 9 h macrophage activation with LPS, in parallel with the decrease in NOS2 expression (Figure 7B). In contrast, addition of CLNO<sub>2</sub> during LPS-induced macrophage activation caused an earlier induction of HO-1 compared with controls (3 compared with 9 h respectively), and resulted in inhibition of NOS2 expression (Figure 7B, compare lanes 2 and 7 of the bottom gel, indicated with arrows). Thus the well-known capacity of HO-1 to modulate NOS2 expression in macrophages [27], together with the fact that nitroalkenes robustly induce HO-1 at low concentrations ([17,20], and the present study), suggest potential HO-1 mitigation of the macrophage NOS2 responses observed in the present study. Two observations might support this contention: first, LNO<sub>2</sub> was more potent in inducing HO-1 expression and inhibiting NOS2 expression than CLNO<sub>2</sub>. Secondly, at low micromolar concentrations (5  $\mu$ M) CLNO<sub>2</sub> inhibited NOS2 expression only when pre-incubated with cells for 20 h, a condition also required for detecting HO-1 induction (results not shown). Mechanisms associated with the induction of HO-1 by nitroalkenes in macrophages are unknown; they might involve Nrf2 (nuclear factor-erythroid 2 p45 subunit-related factor 2) activation and/or require synergy between the cAMP-dependent response element



**Figure 6** Effects of CLNO<sub>2</sub> (A), LNO<sub>2</sub> (B) and rosiglitazone (C) on CD36 expression by monocytes

THP-1 cells were differentiated with 50 ng/ml PMA in the presence of the molecules indicated. After 20 h incubation, cells were stained for CD36 or CD45 and analysed by flow cytometry. Top panels showed a representative histogram plot obtained for CD36 analysis. Bottom panels show CD36 and CD45 expression as relative increases (fluorescence of treated cells/fluorescence of control cells); results are expressed as the means  $\pm$  S.D. ( $n = 3$ ). \* indicates a statistical significance ( $P < 0.05$ ) compared with control.

CRE and AP-1 (activator protein 1) sequences in the HO-1 promoter region [36,37].


### CLNO<sub>2</sub> and LNO<sub>2</sub> inhibit LPS-induced NF- $\kappa$ B signalling in macrophages

An additional mechanism that could contribute to CLNO<sub>2</sub> and LNO<sub>2</sub>-induced inhibition of NOS2 and cytokine expression is a Michael addition reaction of this electrophilic species with transcriptional factors, preventing expression of downstream gene products [38]. In this regard, the inhibition of macrophage cytokine secretion by nitro-fatty acids via post-translational electrophilic alkylation of critical thiols of the NF- $\kappa$ B p65 subunit has been observed [17]. Since the transcription factor NF- $\kappa$ B contributes to LPS-induced NOS2 gene expression [39], we explored whether CLNO<sub>2</sub> and LNO<sub>2</sub> were capable of inhibiting NF- $\kappa$ B activation under the cell activation conditions used for studying NOS2 expression. Both CLNO<sub>2</sub> and LNO<sub>2</sub> did not inhibit NF- $\kappa$ B activation when added concurrently to cells with LPS (Figure 8A). In contrast, a marked inhibition of NF- $\kappa$ B activation was observed when macrophages were pretreated with both nitroalkene derivatives for 20 h prior to LPS stimulation (Figure 8B), supporting that nitroalkene effects on NF- $\kappa$ B

activation are not an immediate/early event. It has been shown that CO, one of the products resulting from HO-1 activity, inhibits LPS-induced activation of NF- $\kappa$ B by preventing the phosphorylation and degradation of the regulatory subunit I $\kappa$ B $\alpha$  (inhibitor of NF- $\kappa$ B) [27,35]. Therefore the contribution of HO-1 to nitroalkene inhibition of NOS2 expression might occur via CO-mediated inhibition of NF- $\kappa$ B.

### Concluding remarks


Overall, the results of the present study support the concept that 'NO increases the breadth of reactions that transduce 'redox signalling'', thus linking the metabolic and immune status of cells with information transfer reactions. The nitration of CL to yield CLNO<sub>2</sub> upon activation of macrophages with pro-inflammatory stimuli affirms that the oxidative and nitrative reactions characteristic of inflammation also induce lipid nitration. In particular, the generation of CLNO<sub>2</sub> may be of relevance considering that this molecule would concentrate in hydrophobic environments, where Nef-like decay reactions are limited, to potentially serve as a hydrolysable reserve of esterified LNO<sub>2</sub>. Thus CLNO<sub>2</sub> may mediate cell signalling actions directly or indirectly, by serving as a precursor for subsequent LNO<sub>2</sub> release. These indirect CLNO<sub>2</sub>



**Figure 7** CLNO<sub>2</sub> induced HO-1 expression in macrophages

(A) Mouse J774.1 cells were stimulated with CLNO<sub>2</sub>, LNO<sub>2</sub> or their respective fatty acid precursors at the indicated concentrations. After 20 h stimulation, the presence of HO-1 and actin (control) was analysed in cell lysates by Western blot. (B) Time course of NOS2 and HO-1 expression in LPS-activated macrophages in the absence and presence of CLNO<sub>2</sub>. Mouse J774.1 cells at confluence were stimulated with LPS (1 µg/ml) in the presence or absence of CLNO<sub>2</sub> (25 µM). At different times post-stimulation (3, 6, 9, 12 and 24 h), the presence of NOS2, HO-1 and actin was examined by Western blot. Veh, vehicle.

effects may be significant, inasmuch as LNO<sub>2</sub> was shown to be a more potent modulator of macrophage activation than CLNO<sub>2</sub>, and a robust PPAR $\gamma$  ligand [40]. It remains to be established what specific concentrations of CLNO<sub>2</sub> and LNO<sub>2</sub> are generated during macrophage activation, an insight that will shed light on the physiological relevance of fatty acid nitration during inflammatory responses. We determined that CLNO<sub>2</sub> content in activated macrophages reached ~100–300 nM per 10<sup>6</sup> cells/ml, but this value probably underestimates net cellular content as it was obtained using a method in which losses derived from sample preparation, as well as from nitroalkene decay reactions and Michael addition reactions with cell components, would not be compensated for. It was observed that the concentrations of CLNO<sub>2</sub> required to effectively induce modulatory effects on



**Figure 8** CLNO<sub>2</sub> and LNO<sub>2</sub> inhibited NF- $\kappa$ B activation

LPS-induced activation of NF- $\kappa$ B was analysed in nuclear extracts of activated cells in comparison with controls. Mouse J774.1 cells were stimulated with LPS (1 µg/ml) in the presence of CLNO<sub>2</sub> (25 µM), CL (25 µM), LNO<sub>2</sub> (10 µM), LA (10 µM) or vehicle. The addition of nitroalkenes was made concurrently (A) or prior (20 h; B) to LPS stimulation. Cells were also incubated in the presence of vehicle. After 1 h LPS-stimulation, nuclear extracts were prepared and levels of NF- $\kappa$ B in extracts were determined by Western blot analysis. Top panels correspond to the densitometric analysis of bands and correspond to means  $\pm$  S.D. \* indicates a statistical significance ( $P < 0.05$ ,  $n = 3$ ) compared with control. Veh, vehicle.

macrophage function were in the low micromolar range. This is consistent with previous observations that *in vitro* functional responses to lipophilic stimuli (e.g. prostaglandins and other eicosanoid derivatives) do not reproduce the *in vivo* responses to much lower concentrations of endogenously formed mediators; a significant percentage of which are not expected to efficiently reach critical intracellular targets *in vitro* because of solubility and diffusional limitations and an expectation of alternative decomposition/electrophilic reactions with medium components [38,41]. Thus further studies will be focused on determining the

net concentration of nitrated fatty acid derivatives in activated macrophages, and improving functional assays (i.e. by using phospholipid vesicles for nitroalkene administration). With these caveats in mind, and taking into account the ability of CLNO<sub>2</sub> and LNO<sub>2</sub> to inhibit pro-inflammatory gene expression and induce the expression of cytoprotective enzymes such as HO-1, the formation of lipid nitration derivatives during macrophage activation is viewed to act as an endogenous adaptative signalling mechanism that down-regulates cell oxidative responses and contributes to the control of inflammation.

We thank Gonzalo Peluffo, Rafael Radi and Hugo Cerecetto for helpful discussions, and Horacio Pizarro for technical assistance. This work was supported by grants from the NIH (National Institutes of Health; R03-TW007151 to H.R. and R01-HL58115 and R01-HL64937 to B.A.F.), the Guggenheim Foundation (to H.R.), the Wellcome Trust (to H.R. and V.O.D.), Programa para el Desarrollo de las Ciencias Básicas and Programa de Desarrollo Tecnológico and Fondo Clemente Estable, Uruguay (to A.M.F. and H.R.) and the AHA (American Heart Association; 06654184 to F.J.S.).

## REFERENCES

- Lima, E. S., Di Mascio, P., Rubbo, H. and Abdalla, D. S. (2002) Characterization of linoleic acid nitration in human blood plasma by mass spectrometry. *Biochemistry* **41**, 10717–10722
- Baker, P. R., Schopfer, F. J., Sweeney, S. and Freeman, B. A. (2004) Red cell membrane and plasma linoleic acid nitration products: synthesis, clinical identification, and quantitation. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 11577–11582
- Baker, P. R., Lin, Y., Schopfer, F. J., Woodcock, S. R., Groeger, A. L., Batthyany, C., Sweeney, S., Long, M. H., Iles, K. E., Baker, L. M. et al. (2005) Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. *J. Biol. Chem.* **280**, 42464–42475
- Rubbo, H., Radi, R., Trujillo, M., Telleri, R., Kalyanaram, B., Barnes, S., Kirk, M. and Freeman, B. A. (1994) Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. *J. Biol. Chem.* **269**, 26066–26075
- O'Donnell, V. B., Eiserich, J. P., Chumley, P. H., Jablonsky, M. J., Krishna, N. R., Kirk, M., Barnes, S., Darley-Usmar, V. M. and Freeman, B. A. (1999) Nitration of unsaturated fatty acids by nitric oxide-derived reactive nitrogen species peroxynitrite, nitrous acid, nitrogen dioxide, and nitronium ion. *Chem. Res. Toxicol.* **12**, 83–92
- Schopfer, F. J., Lin, Y., Baker, P. R., Cui, T., Garcia-Barrio, M., Zhang, J., Chen, K., Chen, Y. E. and Freeman, B. A. (2005) Nitro-linoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 2340–2345
- Ricote, M., Huang, J., Fajas, L., Li, A., Welch, J., Najib, J., Witztum, J. L., Auwerx, J., Palinski, W. and Glass, C. K. (1998) Expression of the peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 7614–7619
- Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. and Glass, C. K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature* **391**, 79–82
- Alleva, D. G., Johnson, E. B., Lio, F. M., Boehme, S. A., Conlon, P. J. and Crowe, P. D. (2002) Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor- $\gamma$ : counter-regulatory activity by IFN- $\gamma$ . *J. Leukoc. Biol.* **71**, 677–685
- Castrillo, A. and Tontonoz, P. (2004) PPARs in atherosclerosis: the clot thickens. *J. Clin. Invest.* **114**, 1538–1540
- Castrillo, A. and Tontonoz, P. (2004) Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. *Annu. Rev. Cell Dev. Biol.* **20**, 455–480
- Ricote, M., Villedor, A. F. and Glass, C. K. (2004) Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* **24**, 230–239
- Lehrke, M. and Lazar, M. A. (2005) The many faces of PPAR $\gamma$ . *Cell* **123**, 993–999
- Schopfer, F. J., Baker, P. R., Giles, G., Chumley, P., Batthyany, C., Crawford, J., Patel, R. P., Hogg, N., Branchaud, B. P., Lancaster, Jr, J. R. and Freeman, B. A. (2005) Fatty acid transduction of nitric oxide signaling. Nitro-linoleic acid is a hydrophobically stabilized nitric oxide donor. *J. Biol. Chem.* **280**, 19289–19297
- Lima, E. S., Bonini, M. G., Augusto, O., Barbeiro, H. V., Souza, H. P. and Abdalla, D. S. (2005) Nitrated lipids decompose to nitric oxide and lipid radicals and cause vasorelaxation. *Free Radical Biol. Med.* **39**, 532–539
- Lim, D. G., Sweeney, S., Bloodworth, A., White, C. R., Chumley, P. H., Krishna, N. R., Schopfer, F., O'Donnell, V. B., Eiserich, J. P. and Freeman, B. A. (2002) Nitro-linoleate, a nitric oxide-derived mediator of cell function: synthesis, characterization, and vasomotor activity. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 15941–15946
- Cui, T., Schopfer, F. J., Zhang, J., Chen, K., Ichikawa, T., Baker, P. R., Batthyany, C., Chacko, B. K., Feng, X., Patel, R. P. et al. (2006) Nitrated fatty acids: endogenous anti-inflammatory signaling mediators. *J. Biol. Chem.* **281**, 35686–35698
- Coles, B., Bloodworth, A., Eiserich, J. P., Coffey, M. J., McLoughlin, R. M., Giddings, J. C., Lewis, M. J., Haslam, R. J., Freeman, B. A. and O'Donnell, V. B. (2002) Nitro-linoleate inhibits platelet activation by attenuating calcium mobilization and inducing phosphorylation of vasodilator-stimulated phosphoprotein through elevation of cAMP. *J. Biol. Chem.* **277**, 5832–5840
- Coles, B., Bloodworth, A., Clark, S. R., Lewis, M. J., Cross, A. R., Freeman, B. A. and O'Donnell, V. B. (2002) Nitro-linoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. *Circ. Res.* **91**, 375–381
- Wright, M. M., Schopfer, F. J., Baker, P. R., Vidyasagar, V., Powell, P., Chumley, P., Iles, K. E., Freeman, B. A. and Agarwal, A. (2006) Fatty acid transduction of nitric oxide signaling: nitro-linoleic acid potently activates endothelial heme oxygenase 1 expression. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 4299–4304
- Esterbauer, H., Gebicki, J., Puhl, H. and Jurgens, G. (1992) The role of lipid peroxidation and antioxidants in oxidative modification of LDL. *Free Radical Biol. Med.* **13**, 341–390
- Lima, E. S., Di Mascio, P. and Abdalla, D. S. (2003) Cholesteryl nitro-linoleate, a nitrated lipid present in human blood plasma and lipoproteins. *J. Lipid Res.* **44**, 1660–1666
- Corraliza, I. M., Campo, M. L., Fuentes, J. M., Campos-Portuguez, S. and Soler, G. (1993) Parallel induction of nitric oxide and glucose-6-phosphate dehydrogenase in activated bone marrow derived macrophages. *Biochem. Biophys. Res. Commun.* **196**, 342–347
- Bligh, E. G. and Dyer, W. L. (1959) A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* **37**, 911–917
- Green, L. C., Wagner, D. A., Glogowski, J., Skipper, P. L., Wishnok, J. S. and Tannenbaum, S. R. (1982) Analysis of nitrate, nitrite, and [<sup>15</sup>N]nitrate in biological fluids. *Anal. Biochem.* **126**, 131–138
- Chatton, J. Y. and Broillet, M. C. (2002) Detection of nitric oxide production by fluorescent indicators. *Methods Enzymol.* **359**, 134–148
- Lee, T. S., Tsai, H. L. and Chau, L. Y. (2003) Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxy- $\Delta$ 12,14-prostaglandin J2. *J. Biol. Chem.* **278**, 19325–19330
- Kraemer, F. B., Tavangar, K., Gandjei, R. K., Kirlaw, K. and Behr, S. R. (1990) Effects of activation on lipid and lipoprotein metabolism in murine macrophages. *Arteriosclerosis* **10**, 8–16
- Hinz, B., Brune, K. and Pahl, A. (2003) 15-Deoxy- $\Delta$ 12,14-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR- $\gamma$ -independent mechanism. *Biochem. Biophys. Res. Commun.* **302**, 415–420
- Chen, C. W., Chang, Y. H., Tsi, C. J. and Lin, W. W. (2003) Inhibition of IFN- $\gamma$ -mediated inducible nitric oxide synthase induction by the peroxisome proliferator-activated receptor gamma agonist, 15-deoxy- $\Delta$ 12,14-prostaglandin J2, involves inhibition of the upstream Janus kinase/STAT1 signaling pathway. *J. Immunol.* **171**, 979–988
- Trostchansky, A., Souza, J. M., Ferreira, A., Ferrari, M., Blanco, F., Trujillo, M., Castro, D., Cerecetto, H., Baker, P. R., O'Donnell, V. B. and Rubbo, H. (2007) Synthesis, isomer characterization, and anti-inflammatory properties of nitroarachidonate. *Biochemistry* **46**, 4645–4653
- Zhang, H., Snead, C. and Catravas, J. D. (2001) Nitric oxide differentially regulates induction of type II nitric oxide synthase in rat vascular smooth muscle cells versus macrophages. *Arterioscler. Thromb. Vasc. Biol.* **21**, 529–535
- Foresti, R. and Motterlini, R. (1999) The heme oxygenase pathway and its interaction with nitric oxide in the control of cellular homeostasis. *Free Radical Res.* **31**, 459–475
- Sarady, J. K., Otterbein, S. L., Liu, F., Otterbein, L. E. and Choi, A. M. (2002) Carbon monoxide modulates endotoxin-induced production of granulocyte macrophage colony-stimulating factor in macrophages. *Am. J. Respir. Cell Mol. Biol.* **27**, 739–745
- Ryter, S. W., Alam, J. and Choi, A. M. (2006) Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. *Physiol. Rev.* **86**, 583–650
- Villacorta, L., Zhang, J., Garcia-Barrio, M. T., Chen, X. L., Freeman, B. A., Chen, Y. E. and Cui, T. (2007) Nitro-linoleic acid inhibits vascular smooth muscle cell proliferation via the Keap1/Nrf2 signaling pathway. *Am. J. Physiol. Heart Circ. Physiol.* **293**, H770–H776

- 37 Freeman, B. A., Baker, P. R., Schopfer, F. J., Woodcock, S. R., Napolitano, A. and d'Ischia, M. (2008) Nitro-fatty acid formation and signaling. *J. Biol. Chem.* **283**, 15515–15519
- 38 Batthyany, C., Schopfer, F. J., Baker, P. R., Duran, R., Baker, L. M., Huang, Y., Cervenansky, C., Braunchaud, B. P. and Freeman, B. A. (2006) Reversible post-translational modification of proteins by nitrated fatty acids *in vivo*. *J. Biol. Chem.* **281**, 20450–20463
- 39 Xie, Q. W., Kashiwabara, Y. and Nathan, C. (1994) Role of transcription factor NF- $\kappa$ B/Rel in induction of nitric oxide synthase. *J. Biol. Chem.* **269**, 4705–4708
- 40 Li, Y., Zhang, J., Schopfer, F. J., Martynowski, D., Garcia-Barrio, M. T., Kovach, A., Suino-Powell, K., Baker, P. R., Freeman, B. A., Chen, Y. E. and Xu, H. E. (2008) Molecular recognition of nitrated fatty acids by PPAR $\gamma$ . *Nat. Struct. Mol. Biol.* **15**, 865–867
- 41 Baker, L. M., Baker, P. R., Golin-Bisello, F., Schopfer, F. J., Fink, M., Woodcock, S. R., Braunchaud, B. P., Radi, R. and Freeman, B. A. (2007) Nitro-fatty acid reaction with glutathione and cysteine. Kinetic analysis of thiol alkylation by a Michael addition reaction. *J. Biol. Chem.* **282**, 31085–31093

---

Received 18 April 2008/30 July 2008; accepted 1 August 2008


Published as BJ Immediate Publication 1 August 2008, doi:10.1042/BJ20080701

## SUPPLEMENTARY ONLINE DATA



# Macrophage activation induces formation of the anti-inflammatory lipid cholesteryl-nitrolinoleate


Ana M. FERREIRA\*, Mariana I. FERRARI\*, Andrés TROSTCHANSKY†, Carlos BATTYANY†§, José M. SOUZA†, María N. ALVAREZ†, Gloria V. LÓPEZ‡, Paul R. S. BAKER§, Francisco J. SCHOPFER§, Valerie O'DONNELL||, Bruce A. FREEMAN§<sup>1</sup> and Homero RUBBO†<sup>1</sup>

\*Department of Immunology, Faculty of Sciences, University of the Republic, Montevideo 11400, Uruguay, †Department of Biochemistry, Center for Free Radical and Biomedical Research, Faculty of Medicine, University of the Republic, Montevideo 11800, Uruguay, ‡Department of Organic Chemistry, Faculty of Sciences, University of the Republic, Montevideo 11800, Uruguay, §Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, U.S.A., and ||Department of Medical Biochemistry, University of Wales College of Medicine, Cardiff CF14 4XN, U.K.




<sup>1</sup> Correspondence may be addressed to either of these authors (email hrubbo@fmed.edu.uy or freerad@pitt.edu).






**Figure S1** Spectroscopic data for CLNO<sub>2</sub>bottom and CLNO<sub>2</sub>top

The labelled chemical shift values assigned confirm that nitration occurred on the acyl moiety of CL and that CLNO<sub>2</sub>bottom and CLNO<sub>2</sub>top correspond to the nitroalkene isomers shown.




**Figure S2** Effect of CLNO<sub>2</sub> isomers (top and bottom) on •NO generation by activated macrophages

Mouse J774.1 macrophages were activated with LPS in the presence of the indicated molecules. After 5 h incubation, •NO was measured by fluorimetry to evaluate NOS2 activity. The •NO generation (fluorescence units) was plotted against time (CLNO<sub>2</sub> and CL, 50 μM; LNO<sub>2</sub> and LA, 10 μM). Results are representative of three independent experiments.



**Figure S3** Effect of nitrated lipids on cell viability

THP-1 cells were activated with PMA in the presence of the indicated molecules as described in the Materials and methods section of the main paper. After 20 h incubation, cells were analysed for viability by measuring the mitochondrial-dependent reduction of MTT to formazan. Briefly, MTT was added to cells (final concentration 0.2 mg/ml) and cells were then incubated at 37 °C for 4 h. After removing the medium, formazan crystals were dissolved in DMSO and the absorbance at 570 nm was read using a microplate spectrophotometer. Results are expressed as the percentage of the control (stimulated cells in the presence of the vehicle), and correspond to the mean ± S.D. ( $n = 3$ ).



**Figure S4 Effect of chloroquine on the ability of CLNO<sub>2</sub> to inhibit NOS2 expression by macrophages**

Mouse J774.1 cells were pretreated (2 h) with chloroquine (20 μg/ml) and then stimulated with LPS (1 μg/ml) in the presence of CLNO<sub>2</sub> (50 μM) or vehicle. After 5 h stimulation, NOS2 activity was measured following \*NO generation by fluorimetry. Results are expressed as the mean ± S.D. ( $n = 3$ ; \*\* $P < 0.01$ , \* $P < 0.05$ ).

Received 18 April 2008/30 July 2008; accepted 1 August 2008

Published as BJ Immediate Publication 1 August 2008, doi:10.1042/BJ20080701